Based on internal projections for demand, the two companies have approved about $150 million in additional investments to ...

Legend Biotech is building a new $150 million manufacturing plant, with its partner Johnson & Johnson, with the goal of ...

Carvykti's success boosts Legend Biotech Corporation's Q4 2024 sales to $334M, solidifying market position. Click to find out ...

Unlocking manufacturing capacity will be key for Legend Biotech and Johnson and Johnson in achieving their goal of reaching ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

Legend Biotech’s (LEGN) shares have surged over 10% in the past few days, spurred by the company’s latest earnings report, thanks to ...

But that decision was made alongside the expanded approval of Carvykti to second-line use in multiple myeloma. Despite this advantage, Carvykti is associated with a movement disorder side effect ...

CARVYKTI® net trade sales of approximately $334 million and $963 million for the fourth quarter and full year 2024, respectivelyOver 5,000 ...

Q4 2024 Earnings Call Transcript March 11, 2025 Legend Biotech Corporation beats earnings expectations. Reported EPS is $0.08 ...

However, Abecma has faced increasing competition in the multiple myeloma space, particularly from Johnson & Johnson and Legend Biotech’s BCMA CAR-T Carvykti (ciltacabtagene autoleucel).

Caroline Paul; Associate Director of Investor Relations; Nanjing Legend Biotechnology Co Ltd Ying Huang; Chief Executive Officer; Nanjing Legend Biotechnology Co Ltd Jessie Yeung; Interim Chief ...

Legend Biotech Corp (LEGN) reports a 110% increase in CARVYKTI sales, outlines expansion strategies, and anticipates ...